MacroGenics Inc ((MGNX)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: MacroGenics Inc. is conducting a Phase 2 study titled ‘A Phase 2 Multicohort Study to Evaluate Lorigerlimab in Participants With Advanced Solid Tumors.’ The study aims to assess the efficacy and safety of lorigerlimab, a bispecific DART protein, in patients with platinum-resistant ovarian cancer and clear cell gynecologic cancer. This research is significant as it targets cancers that are resistant to conventional platinum-based treatments.
Intervention/Treatment: The intervention being tested is lorigerlimab, a biological treatment administered intravenously every 21 days. Lorigerlimab is designed to bind PD-1 and CTLA-4, potentially enhancing the immune response against cancer cells.
Study Design: This interventional study is non-randomized with a parallel assignment model. It is open-label, meaning no masking is involved, and its primary purpose is treatment-focused. Participants are divided into two experimental cohorts based on their cancer type.
Study Timeline: The study began on December 9, 2024, with the latest update submitted on September 16, 2025. These dates are crucial as they indicate the study’s progression and the timeliness of the data being collected.
Market Implications: The ongoing study of lorigerlimab could significantly impact MacroGenics’ stock performance and investor sentiment, especially if the results demonstrate positive outcomes. Success in this study might position MacroGenics favorably against competitors in the oncology sector, potentially leading to increased market share and investor interest.
The study is currently recruiting, with further details available on the ClinicalTrials portal.